🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Get your LAG 3 away from my T Cells!! Proximity between LAG-3 and the T cell receptor guides suppression of T cell activation and autoimmunity: Cell ⁦Cell Press⁩ cell.com/cell/abstract/…

VHL-associated RCC is not indolent. We need better than surveillance. European Urology European Association of Urology (EAU) Amer. Urol. Assn. ESMO - Eur. Oncology ASCO VHL Alliance KidneyCAN IKCC Kidney Cancer Kidney Cancer National Cancer Institute Mark Ball, MD, FACS OncoAlert Oncology Brothers doi.org/10.1016/j.euru…

What is on the Horizon for Kidney Cancer? Emre Yekedüz Dana-Farber Dana-Farber News #KidneyCancer #MedTwitter curetoday.com/view/what-is-o…

🚨Just weeks after #ASCO25, the latest highlights in genitourinary cancers are now available. The newly released The ASCO Post provides a quick and concise overview. 👀Take another look, this time from our perspective w/ Yüksel Ürün 👉bit.ly/46lgtHK ASCO

🚨 NEW in #EuropeanUrology By Saum Ghodoussipour Roger Li Sarah P. Psutka MD MS Trinity J. Bivalacqua Joan Palou Redorta et al Can novel intravesical therapies change the game for non–muscle-invasive bladder cancer? This systematic review explores: ✅ BCG-based combos ✅ Gene & immune therapies ✅ Innovative drug

Applications for Conquer Cancer, the ASCO Foundation grants and awards are officially open! Funding is available for researchers at every career stage. Learn more and apply now! brnw.ch/21wTOAb #ResearchFunding #OncologyResearch

Bladder Cancer 101: Immunotherapy - 2025 GU Cancers Program - youtu.be/0AbZOUP60R8 For this video, Dr. Karine Tawagi discusses immunotherapy as one option for treating bladder cancer. For more, please visit cancerGRACE.org. To join the conversation, visit

Connect w/ peers who share your interest in building leadership skills & participate in what could be, as Sumanta K. Pal, MD, FASCO considers it, “one of the most gratifying experiences of [your] career”: the ASCO Leadership Development Program. Applications now open! brnw.ch/21wTQsD

Early detection of renal cell carcinoma: a novel cell-free DNA fragmentomics-based liquid biopsy assay in ESMO Open. Mostly early stage RCC, promising non-invasive tool based on 3 cfDNA features integrated into a stacked ensemble ML model. esmoopen.com/article/S2059-…

📣 Calling future oncologists who have completed at least 1y of #oncology training! Apply by 7/9/25 to attend FDA Oncology-ASCO Fellows’ Day Workshop: asco.smapply.org/prog/2025-2026… 👉 9/25/25: in person (ASCO headquarters, DC area) or 👉 1/29/26: virtual See you there! #MedTwitter

1/ Thrilled to share our work on Chromophobe RCC (ChRCC) and Renal Oncocytic Neoplasms (RONs) out Journal of Clinical Oncology !!! Incredibly thankful to my mentors David Braun Toni Choueiri, MD Eli Van Allen and all co-authors Dana-Farber BIDMC IM Residency Yale University Brigham and Women's Hospital Link: ascopubs.org/doi/10.1200/JC…

Ipi/nivo vs VEGF TKI in non-clear cell RCC Annals of Oncology The 1st randomised IO data in these cancers, establishing IO. It’s +ve but not overwhelming. Some minor design issues too.VEGF/PD1 combos are probably better, but those studies were not randomised sciencedirect.com/science/articl…

1/ Recently, our lab has worked with outstanding groups (#TeamScience) to address some key questions in kidney cancer immunobiology: Can we use machine-learning approaches to classify RCC and predict response? Cancer Cell What drives exceptional response with immunotherapies?

9/ Very grateful to the outstanding students, postdocs, and close collaborators for these efforts, along with funding sources including NIH National Cancer Institute Department of Defense 🇺🇸 CDMRP Gateway for Cancer Research Kidney Cancer , and most of all, the patients and their families. Lots of work to be done!

💡Starting out in thoracic oncology? The IASLC Communications Committee proudly brings you: ‘50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic’ A whistlestop tour of key advances, distilled by global leaders JTO & JTO CRR OncoAlert #LCSM jto.org/article/S1556-…

GU Malignancy Highlights from #ASCO25 w/ Tian Zhang, MD, MHS! ✅ #Keynote564 ✅ #AMPLITUDE ✅ #ARANOTE ✅ #NIAGARA Full Discussion: - oncbrothers.com/asco2025-GU - Also on the “Oncology Brothers” podcast #gusm ASCO #OncTwitter #MedTwitter OncUpdates #Happy4th

⚠️Publication alert ⚠️ Our new paper from "Turkish Oncology Group Kidney Cancer Consortium" just OUT! Huge congrats to Serhat Sekmek and all the team! Yüksel Ürün OncoAlert #KidneyCancer #MedX #Oncology 👉doi.org/10.1080/175074…

Can metformin boost survival in metastatic hormone-sensitive prostate cancer? 🔑 : A win for metabolic health, but not a game-changer (yet). ❌ No significant OS benefit (HR 0.91, p=0.15) ✅ Reduced ADT-related metabolic side effects 💊 Safe & well-tolerated (mostly GI issues)

Honored and humbled to accept a new role as Division Chief for Hematology & Oncology at Georgetown starting next month. Excited for all that the future holds for Georgetown University Georgetown Lombardi with the best colleagues one could ask for.

"After 20 years of leadership, John Marshall, will be stepping down as the division chief of Medical Oncology at MedStar Georgetown University Hospital. Dr. Marshall will remain in practice with our GI oncology disease group and will continue to serve as the chief medical officer